Abstract
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
MeSH terms
-
Age Factors
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / standards
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / analysis*
-
Biomarkers, Tumor / genetics
-
Biomarkers, Tumor / immunology
-
Cytogenetic Analysis / standards
-
Disease-Free Survival
-
Graft vs Host Disease / immunology
-
Graft vs Host Disease / prevention & control
-
HLA Antigens / immunology
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Hematopoietic Stem Cell Transplantation / standards*
-
Histocompatibility Testing / standards
-
Humans
-
Leukemia, Myeloid, Acute / diagnosis
-
Leukemia, Myeloid, Acute / mortality
-
Leukemia, Myeloid, Acute / therapy*
-
Medical Oncology / standards*
-
Middle Aged
-
Remission Induction / methods
-
Risk Assessment / standards
-
Transplantation, Homologous / adverse effects
-
United States
Substances
-
Biomarkers, Tumor
-
HLA Antigens